Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BiomX Inc.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.
- Drug Discovery Tools
- Other Names / Subsidiaries
- BiomX Ltd.
- Chardan Healthcare Acquisition Corp.
- RondinX Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.